Drug delivery is evolving at a rapid rate with new drug product formulations being discovered frequently. Advanced drug delivery deals with developing solutions for new entities in therapeutic pharmacology such as protein and peptides and other novel compounds targeting drugs to specific disease sites including gene therapy. Treatments for chronic conditions and growth in patient-administered drugs are factors leading to greater focus on ease-of-use and convenience.
Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) details the types of drug delivery systems, technologies and products utilizing advanced drug delivery systems The report describes the industry, its relationship to various healthcare channels, and the trends for the future.
The advanced drug delivery market is two-fold. First of all it identifies drug delivery technology Secondly, it identifies products in the pharmaceutical arena that utilize those drug delivery technologies. Because drug delivery technology is an integral part of sales of pharmaceuticals and drug delivery technology cannot exist without pharmaceuticals, revenues have been reported that include pharmaceutical sales. This report will provide market data that includes the pharmaceutical revenues of those products that utilize advanced drug delivery.
In this report, the advanced drug delivery market is divided into three main segments and market estimates are provided for indications within each category:
The following types of polymer delivery drugs are segmented within this report.
The following companies are profiled in the report:
All market data pertains to the worldwide market at the manufacturers’ level and was measured in U.S. dollars. The base year for data was 2010. Historical data are provided for 2006 through 2009, with forecast data provided for 2010 through 2014. Compound annual growth rates (CAGR) are provided for the 2006-2010, 2010-2014 and 2006-2014.
All Kalorama reports advertise the single user price. Use is limited to one user. We also feature department and global pricing for reports that we be utilized by more than one user at your company. Please consult ask your sales representative or select the correct license on our website.
For Kalorama's take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information's Key Point Blog at http://kaloramakeypoint.blogspot.com/
Growth in biological drugs and gene therapy is driving developments in the advanced drug delivery market. A report from healthcare market research publisher Kalorama Information, Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies), finds that nanotechnology is the most promising area in the $60.6 billion global market for advanced drug delivery products.
Advanced drug delivery strategies are taking advantage of new entities in therapeutic pharmacology, such as proteins and peptides and other novel compounds that target drugs to specific disease sites. For Example, gene therapy has shown promise, but its development is stymied by the lack of appropriate delivery methods.
"The goal of advanced drug delivery systems is to deploy medications intact to specifically targeted parts of the body through a medium that can control the therapy's administration by means of a physiological chemical trigger," said Melissa Elder, an analyst for Kalorama Information and the author of the study. "To achieve this goal, researchers are turning to advances in micro and nanotechnology."
During the last decade, polymeric microspheres, polymer micelles, and hydrogel-type nanocarriers have all been shown to be effective in enhancing drug targeting specificity, lowering drug toxicity, improving treatment absorption rates, and providing protection for drugs against biochemical degradation.
"Some areas of nanotechnology are more advanced than others," said Elder. "However, all are playing a large role in diagnostics, pharmaceuticals and therapeutics."
Kalorama finds sales in nanomedicine are expected to spike with the highly anticipated development of monoclonal antibodies for respiratory indications, psoriasis, prevention of transplant rejection and cancer. Over twenty companies have patents in this area of development, indicating a propitious future outlook. With an increasing number of disease and cancer patients, pharmaceutical companies are facing a difficult challenge in the delivery of breakthrough medications. There is an immense revenue opportunity in nanotechnology capable of providing targeted drug delivery.
Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) analyzes several trends, including molecular imprinted polymers, antibiotic biodegradable implants, hot-melt extrusion technology, sorbent technology, and gene therapy drug delivery. The report concentrates on liposome and polymer drug delivery, as well as monoclonal antibodies.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook